News

Three-year durability data emerge for two distinct approaches to RP

Diastolic perfusion pressure emerges as the strongest predictor of myocardial strain in a recent study.

ECG-synchronized Doppler holography provides repeatable measurements of the retinal blood flow

The poster looked into the LLM's potential for biases in gender and race when it came to its knowledge of retinitis pigmentosa.

Srinivas Sadda, MD, FARVO, immediate past president of ARVO, discusses the impact the organization has had on his career and how he wants to help the next generation.

Kaden Bunch, a fourth-year medical student from the Warren Alpert Medical School of Brown University, talked about his poster on large language models and the effectiveness of diagnosing red eye diseases.

At this year's ARVO meeting in Denver, Colorado, Giulia Corradetti spoke on how baseline OCT biomarkers can predict anatomic response in neovascular age-related macular degeneration when treated with faricimab.

In addition to ChatGPT for Clinicians, OpenAI introduced ChatGPT for Healthcare earlier this year.

Researchers noted growing evidence supporting an additional role for B vitamins.

New SOL-X extension follows AXPAXLI implant in wet AMD for 3 years, probing 24-week dosing durability, safety and vision protection.

According to the company, the NDA submission is supported by data from the phase 3 DRAGON trial.

Melding ophthalmology and neurology

New expert‑led series explores how ophthalmic innovations move from early development to market‑ready therapies through cross‑functional collaboration.

Phase 3 data show brolucizumab outperforms laser for PDR vision preservation, with fewer adverse events—while monitoring inflammation risk.

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

A tissue-sparing technique using a triple-layer decellularized basement membrane is associated with shorter OR time, rapid recovery, and no reported recurrences in a retrospective series.

The company noted it expects topline results in June 2026.

CMS assigns billing code to support reimbursement for the keratoconus therapy.

Quesada discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the role of integrated OCT imaging.

Zaman discusses the positive topline results from a phase 1/2 study of the BIM-IOL system, during which it successfully reduced IOP in patients with OAG or OHT.

An analysis of lifitegrast trial subgroups showed that earlier treatment and milder baseline disease were associated with faster and greater symptom improvement.

Data from a recent trial of the OmniVu Lens System was presented at ASCRS 2026, featuring positive and sustained vision endpoints.

SOL-1 data show AXPAXLI extends wet AMD control, delaying fluid rebound and reducing rescue injections while sustaining vision through 52 weeks.

Combining peristaltic and Venturi pump technology during phacoemulsification may reduce ultrasound time and support endothelial preservation.